Showing results (221-230 of 399) with videos related to

Sort By:
Pageof 40
Blood|May 5, 2018
High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AMLSanjay S Patel, Frank C Kuo, Christopher J Gibson, et al.
Blood|June 5, 2004
Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AMLJingrui Jiang, J Guillermo Paez, Jeffrey C Lee, et al.
Haematologica|January 8, 2026
Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemiaElias Jabbour, Karamjeet S Sandhu, Paul Shaughnessy, et al.
Blood Advances|April 12, 2024
Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALLYaqi Zhao, A Douglas Laird, Kathryn G Roberts, et al.
Leukemia & Lymphoma|March 15, 2022
Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclaxEvan C Chen, Yiwen Liu, Courtney E Harris, et al.
Leukemia|April 9, 2025
Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final resultsJorge E Cortes, Fabian Lang, Delphine Rea, et al.
Blood|December 3, 2017
A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemiaEytan M Stein, Roland B Walter, Harry P Erba, et al.
British Journal of Haematology|September 27, 2014
Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemiaMarc R Mansour, Casie Reed, Amy R Eisenberg, et al.
American Journal of Hematology|September 2, 2022
Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemiaHagop M Kantarjian, Elias Jabbour, Michael Deininger, et al.
Cell|June 4, 2009
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cellsClaudia Scholl, Stefan Fröhling, Ian F Dunn, et al.
Pageof 40